For over two decades, the laboratory standard to determine ‘acceptable’ blood culture contamination performance has been set at <3% of the total number of blood cultures drawn. In an Emergency Department that performs 10,000 blood cultures per year, a 3.0% contamination rate translates to more than 300 patients that may be treated with unnecessary antibiotics with attendant risks of secondary infections such as C. diff, multidrug-resistant organisms and other antibiotic-associated complications.
It is estimated that blood culture contamination results in over $1 million dollars in avoidable costs to an average-sized (250-300 bed) hospital every year. This estimate doesn’t include the impact on key Centers for Medicare and Medicaid Services (CMS) quality outcome metrics, such as the public reporting of false positive CLABSIs and MRSA bacteremia that result in associated Healthcare Associated Condition (HAC) financial penalties. So, what about a 3% blood culture contamination rate is good for the patient? Not a thing. We now have evidence that shows us the bar has been moved and this outdated goal must be abandoned.
Magnolia Medical is committed to empowering healthcare providers with advanced technologies that virtually eliminate false-positive diagnostic results for sepsis, the associated patient safety risks, and avoidable costs to our healthcare system. Inventors of the Initial Specimen Diversion technology platform for blood culture collection and contamination prevention, the company has amassed an IP portfolio including more than 60 issued method, apparatus and design patents with over 50 additional patent applications pending.